Business Context and Reporting Period
This Form 8-K was filed by Neoleukin Therapeutics, Inc. (trading symbol: NLTX) on March 20, 2020. The report addresses a change in the company's independent registered public accounting firm. The company is incorporated in Delaware and operates primarily in the United States following a merger completed on August 8, 2019.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Accountant Resignation: Deloitte LLP resigned as the independent registered public accounting firm effective March 20, 2020.
- Successor Appointment: The Audit Committee appointed Deloitte & Touche LLP as the successor independent registered public accounting firm.
- Rationale: The change was made in recognition that the company's financial operations and team have transitioned to be primarily located in the United States following the 2019 merger.
Guidance, Outlook, and Risks
Audit History: Deloitte LLP's reports on the consolidated financial statements for the years ended December 31, 2019, and 2018, contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
Disagreements: The company reported no disagreements with Deloitte LLP during the two most recent fiscal years or through the date of this report regarding accounting principles, financial statement disclosure, or auditing scope.
Reportable Events: There were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K during the relevant periods.
Consultations: The company has not consulted with Deloitte & Touche LLP regarding accounting principles for specified transactions or potential audit opinions prior to this appointment.
Investor Verification Checklist
- Verify the transition of audit responsibilities from Deloitte LLP to Deloitte & Touche LLP.
- Confirm that the resignation was not due to any disagreements on accounting or auditing matters.
- Review the letter from Deloitte LLP (Exhibit 16.1) filed with the SEC for their official concurrence with the company's disclosures.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.